Emergent BioSolutions Wins $24 Million BARDA Contract for Anthrax Vaccine

MT newswire2026/09/01 12:17

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

08:17 AM EDT, 09/01/2026 (MT Newswires) -- Emergent BioSolutions (EBS) said Tuesday it won a contract modification worth about $24 million from Biomedical Advanced Research and Development Authority to supply Cyfendus anthrax vaccine for US preparedness efforts. The company said the vaccine was approved by the US Food and Drug Administration in 2023 for post-exposure prevention of anthrax in adults ages 18 to 65 when used with recommended antibiotics.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

The U.S. Energy Information Administration (EIA) has raised its forecast for average Brent crude oil prices in 2026 and 2027 to $97 and $86, respectively, reflecting pressures from global inventory declines, Middle East supply disruptions, and rising transportation costs. As oil production in the Middle East gradually recovers and global inventories rebound from low levels, the EIA expects the average spot price of Brent crude to fall to $87 per barrel in the second quarter of 2027, and further decline to $77 per barrel by the fourth quarter.

华尔街见闻•2026/11/10 18:41